Cabotegravir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cabotegravir
Cabotegravir (GSK744).svg
Cabotegravir ball-and-stick model.png
Names
IUPAC name
N-((2,4-Difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
Identifiers
3D model (JSmol)
ChemSpider
KEGG
UNII
Properties
C19H17F2N3O5
Molar mass 405.358 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N (what is ☑Y☒N ?)
Infobox references

Cabotegravir (USAN[1] and INN[2]; also known as S/GSK1265744 or GSK744) is an investigational new drug under development for the treatment of HIV infection. It is an integrase inhibitor, with a carbamoyl pyridone structure similar to dolutegravir.[3] In investigational studies, the agent has been packaged into nanoparticles (GSK744LAP) conferring an exceptionally long biological half-life of 21–50 days following a single dose. In theory, this would make possible suppression of HIV with dosing as infrequently as once every three months.[4]

Cabotegravir is being examined in the clinical trials HPTN 083 and HPTN 084.[5][6]

References[edit]

  1. ^ "Adopted USANs" (PDF). American Medical Association. Retrieved 19 September 2014.
  2. ^ "WHO Drug Information, Vol. 28, No. 2, 2014" (PDF). WHO Publications. Retrieved 19 September 2014.
  3. ^ Borrell, Brendan (2014). "Long-acting shot prevents infection with HIV analogue". Nature. doi:10.1038/nature.2014.14819.
  4. ^ PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA March 3–6, 2013.
  5. ^ "The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2017-12-02.
  6. ^ "The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2017-12-02.